TIDMSBI
RNS Number : 6251I
SourceBio International PLC
15 December 2020
SourceBio International plc
("SourceBio", the "Company" or the "Group")
Commercial agreement for COVID-19 testing service
Oxford Nanopore's rapid LamPORE COVID-19 test to be made
available via SourceBio accredited lab facilities
SourceBio International plc (AIM:SBI), an international provider
of integrated state of the art laboratory services and products,
announces that it has entered into a strategic commercial
partnership with Oxford Nanopore Technologies Limited ("Oxford
Nanopore"), a leading next generation DNA/RNA sequencing technology
company, to offer a commercially available COVID-19 testing
solution to corporate customers at scale. The test will also be
offered to consumers.
Oxford Nanopore's, CE-marked LamPORE COVID-19 assay, for the
detection of SARS-CoV-2, will be used at SourceBio's
state-of-the-art ISO15189 accredited laboratory facility in
Nottingham to offer a large-scale COVID-19 diagnostic testing
service.
LamPORE COVID-19, a new generation of test, is specifically
designed to detect SARS-CoV-2, the virus that causes COVID-19.
LamPORE is rapid and highly scalable, allowing for high performance
test deployment in both high-throughput, traditional laboratory
settings as well as smaller, more local lab environments -
addressing the need for rapid, routine testing of large numbers of
people. LamPORE has been shown to have sensitivity of 99.1% and
specificity of 99.6%.
In this instance, the LamPORE COVID-19 test is performed from
oropharyngeal and nasopharyngeal swabs which are sent to SourceBio
for assessment and can return a positive or negative result within
24 hours of the laboratory receiving the sample . LamPORE also
includes a built-in human actin control, which enables operators to
discriminate between negative results due to sample collection
errors and negative results due to the absence of SARS-CoV-2
infection.
With options for using LamPORE in a fixed laboratory, or even in
mobile community testing, the service is expected to broaden access
to rapid, high quality testing to support people to return to work,
to visit friends and relatives safely, and potentially assist with
international travel where testing is accepted or required, given
that LamPORE is a high-accuracy molecular test.
The COVID-19 testing service using LamPORE will be offered as an
additional service by SourceBio to complement its existing COVID-19
PCR Testing services which are currently used by a range of
customers.
SourceBio and Oxford Nanopore and are already jointly marketing
this service to potential corporate customers. Potential corporate
customers can register their interest here
https://register.nanoporetech.com/lampore-source-bioscience .
Private individuals can access the service here:
https://coviduk.sourcebioscience.com
Jay LeCoque, Executive Chairman of SourceBio International plc,
said: "The commercial relationship that we have developed with
Oxford Nanopore is a valuable partnership that delivers essential
testing technology and a high-quality service offering at a crucial
time in the worldwide effort to combat and manage the further
spread of Coronavirus. This alliance effectively creates a 'total
solutions approach' for both companies' offerings by combining
Oxford Nanopore's leading LamPORE COVID-19 test with our UKAS
accredited laboratory services. This combination allows both
companies to provide clients with a high quality, highly scalable
and highly professional product and a fully accredited laboratory
services capability."
"The UK Government has minimum standards for private sector
providers of COVID-19 testing and we are delighted to have been
awarded full UKAS ISO15189 status for our COVID testing. Very few
commercial institutions have received this standard and it is a
mandatory requirement from next summer 2021. This underscores the
high standard of our accredited testing services and provides us
with a significant advantage in the market."
Gordon Sanghera, Co-founder and Chief Executive Officer at
Oxford Nanopore Technologies Limited, said: "We are delighted that
high quality COVID-19 testing with LamPORE will now be available
privately in the UK through the high-quality labs of Source
Bioscience. As the UK rolls out a vaccine programme, the importance
of safeguarding workforces and customers, as well as friends and
family, remains a priority for many businesses and individuals. We
are committed to being part of the solution in the UK public and
private sectors, and pleased that our technology can support a
transition back to work, leisure and family life."
Contacts:
SourceBio International plc www.sourcebiointernational.com
Jay LeCoque, Executive Chairman Via Walbrook PR
Tony Ratcliffe, Chief Financial Officer
Liberum (Nominated Adviser and Broker) Tel: 020 3100 2000
Bidhi Bhoma
Joshua Hughes
Euan Brown
Walbrook PR Limited Tel: 020 7933 8780 or sourcebio@walbrookpr.com
Paul McManus / Sam Allen Mob: 07980 541 893 / 07748
651 727
About Oxford Nanopore Technologies Limited
www.nanoporetech.com/about-us
Oxford Nanopore has developed and commercialises a novel
generation of DNA/RNA sequencing technology that provides rich
data, is fast, accessible and easy to use in any location. The
Company's goal is to disrupt the way that biological analyses are
currently performed; to enable the analysis of anything, by anyone,
anywhere.
The palm-sized portable MinION device, and desktop GridION and
PromethION devices, are used in a broad range of scientific
analyses, across human genetics, cancer research, agriculture, food
safety, healthcare and environmental insights. Most recently,
Oxford Nanopore has launched the MinION Mk1C, a fully connected
sequencer with screen and compute, and has also developed the
LamPORE COVID-19 test. www.nanoporetech.com
About SourceBio International plc
www.sourcebiointernational.com
SourceBio is a leading international provider of integrated
state-of-the-art laboratory services and products clients in the
healthcare, clinical, life science research and biopharma
industries, with a focus on improving patient diagnosis, management
and care. Group revenues are derived from four core businesses
areas:
-- Healthcare Diagnostics - histopathology and clinical
diagnostic services for the NHS and private healthcare across the
UK and Ireland.
-- Genomics - DNA sequencing services for pharmaceutical and
biotechnology companies, academia, contract research organisations
(CROs) and other research groups in the UK, Europe and North
America.
-- Stability Storage - shelf-life testing services and equipment
for pharmaceutical and biotechnology companies, contract
manufacturers and analytical testing companies from around the
world but primarily in the UK, Ireland and the USA; and
-- Infectious Disease Testing - since May 2020, the Group has
provided COVID-19 Antigen RT-PCR testing services. These services
passed all of the auditing requirements of the NHS and the
Department of Health and Social Care (DHSC) in April 2020. It is
intended that this offering will potentially provide a broad range
of infectious disease testing across the NHS, private healthcare
and commercial sectors in the future.
More details on Group operations can be found here:
www.sourcebioscience.com
SourceBio International plc (SBI.L) is listed on the AIM market
of the London Stock Exchange.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGRGPGCWPUPUPUC
(END) Dow Jones Newswires
December 15, 2020 02:00 ET (07:00 GMT)
Sourcebio (LSE:SBI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sourcebio (LSE:SBI)
Historical Stock Chart
From Jul 2023 to Jul 2024
